Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.
Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020
Results could provide a new preferred treatment paradigm for this population
Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.
Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.
A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.
Study explores correlations between functional and structural tests
Susan Coultas, PhD, and Preeya Gupta, MD, share their hopes for continued innovation in the ophthalmic space — including dry eye and retina — as well as the importance of the clinical research process.
The application of sub-silicone oil TA crystals over relaxing retinectomy sites is a viable option in patients with complex RD with extreme PVR.
Find out how the LIGHTSITE I results may pave the way for a new treatment approach.
The FDA has issued an emergency use authorization to allow treatment with COVID-19 convalescent plasma for patients who are hospitalized with the disease.
In this second installment, ophthalmologists share how their expectations for "the year of the eye" have compared and contrasted to reality amid the global pandemic.
Retina specialists Caesar Luo, MD, of Bay Area Retina Associates, and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.
Subretinal transplantation of human embryonic stem cells (hESC)-derived retinal pigment epithelial (RPE) cells in patients with AMD and geographic atrophy (GA) appears well tolerated, according to date presented during ARVO 2020.
The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.
The FDA has granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.
Patents gained less vision in clinical practice than patients on clinical trials
Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.
Reductions in macular retinal nonperfusion after anti-VEGF treatment with aflibercept are correlated with improvements in BCVA and central retinal thickness in patients with DR/DME, according to a post-hoc analysis of the VISTA dataset, said Charles C. Wykoff, MD, PhD, during ARVO 2020.
A team of Turkish investigators detected COVID-19 viral material on the environmental surfaces of an ophthalmology examination room despite triage systems to exclude patients with the virus.
Early detection and anti-VEGF treatment of choroidal neovascularization (CNV) in the second eye leads to better mean final visual acuity (VA) with fewer injections at 1 year.
This action will result in 2 separate companies
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.
Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?
Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.
Rates of anxiety and depression increased but were not necessarily tied to disease severity
A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?